“We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments,” a Genentech spokeswoman told STAT.
The company will reduce its workforce by the end of the year.
More articles on supply chain:
6 ways the proposed Republican tax overhaul could impact pharma
3 latest FDA approvals
FDA: EpiPen failures attributed to 7 deaths this year
